

Curriculum Vitae

Personal Information	
Name, Surname	Marzia Bonfanti
Date and Place of Birth	March 25 th , 1985 in Castellanza (Va)
Address	Via A. Da Giussano, 19 – 20157 Olgiate Olona – Italy
Email	dot.marzia.bonfanti@gmail.com
Mobile Phone	(0039) 340 62 64 602
Nationality	Italian
Mother tongue	Italian
Other languages	English (Fluent): Business English Certificate (BEC) – Cambridge English French (Intermediate) German (Basic)
Education	
Ph.D	PhD in Business Administration and Management - University Carlo Cattaneo – LIUC (2010-2014) Thesis “The process of Health Technology Assessment: a proposal of two Hospital-based tools for monitoring and evaluation of Technological Innovation”
Master Degree	MSc in Business Management - University Carlo Cattaneo – LIUC (2007 – 2009) Grade: 110/110 cum laude
Bachelor Degree	BSc in Management – University Carlo Cattaneo – LIUC (2004 – 2007) Grade: 110/110
Professional Experience	
Accountant and data manager	IRCCS Istituto Ortopedico Galeazzi, Via R. Galeazzi, 4 - 20161 Milano (2010) Administrative tasks (budgeting and accounting) related to announcement of selection for Research Project Support for the scientific direction and participation in the research project "Governance of the device acquisition processes and of their use: the case of the hip prosthesis" presented in the strategic program "Tools and methods to regulate the processes of innovation technological, clinical and organizational in the National Health Service - An integrated system of research"
Healthcare Researcher	Éupolis Lombardia – Istituto per la Ricerca, la Statistica e la Formazione Research activities related to the Lombard reform of RHS.
Healthcare consultant	Freelance consultant for pharmaceutical and healthcare companies in the following fields (2012 – present): - Business Administration and Management (activity based costing and benchmarking) - Economic evaluation (Cost-benefit analysis, Cost-effectiveness analysis and Cost-utility analysis) - Budget Impact Analysis of Health Technologies - Health Technology Assessment and Hospital-based HTA - Cost of Illness
Contracted Researcher	Center for Research on Health Economics, Social and Health Care Management (CREMS) - LIUC University (2009 – present) Participation in health economics/healthcare management projects for international organizations, governmental agencies, local health authorities, hospitals and pharmaceuticals companies. Main research areas: <u>HIV</u>

1. Viiv Healthcare (2018-2019): "Reducing Late Presenters Patients rate in Milan Area"
2. Merck (2013-2014): "Cost-utility analysis of Raltegravir vs Darunavir+Ritonavir in experienced HIV-positive patients"
3. Viiv Healthcare (2014-2015): "Analysis of cost-utility and budget impact of Triumeq vs STRs"
4. Viiv Healthcare (2012-2014): "Observational retrospective cost-utility study of Tenofovir/Emtricitabine vs Abacavir/Lamivudine with Atazanavir/Ritonavir or Efavirenz, in naïve HIV-positive patients"
5. Viiv Healthcare (2013): "Health Technology Assessment of Dolutegravir (DTG) in HIV-positive patients"

HCV

1. BMS (2015): "Health Technology Assessment of Daclatasvir in HCV patients"

Antibiotics

1. Angelini (2017): "Organisational, ethical and budget impact analyses of the use of long acting antibiotics for the management of acute bacterial skin and skin structure infections in Italy, Spain and Greece"

Scleroderma

1. GILS Onlus (2016): "Use of intravenous prostanoids in the treatment of scleroderma vascular disease"

Devices

1. Abbott (2016): "CEA and BIA of using Mitraclip (Evalve) for mitral regurgitation"

Radioactive tracers and contrast agents

1. General Electric (2014): "Health economics value proposal of the radioactive tracer ¹²³I fp-cit spect for the diagnosis of neurodegenerative diseases"
2. Bracco (2011): "Health Technology Assessment with cost effectiveness of the use of CEUS (Intraprocedural contrast-enhanced ultrasound) for the assessment of ablation of liver tumors"

Wound Medications

1. Molnlycke Health Care (2012-2014): "Economic evaluation of the use of advanced wound medications in hospitals"

Oncology

1. Local Health Authority Varese (2013): "Cost-effectiveness analysis of taking charge of hereditary cancers of the breast and colon: a pilot study of DIPO in Varese"

Healthcare Management

1. Assobiomedica (2018-2019): "Development of a model for the innovation and sustainability of complex instrumentation for diagnostic imaging in the NHS"
2. Pfizer (2016): "Course of the research for the introduction of MCDA models (Multi Criteria Decision Analysis) in procurement processes of goods and services in public health"
3. N.G.C, Medical (2012-2014): "Benchmarking of procedures provided by in service Hemodynamic wards vs. not in service Hemodynamic wards in Lombard hospitals"
4. Local Health Authority Varese (2013): "Hypothesis of a diagnostic path and home care of obstructive sleep apnea syndrome (OSAS).
5. Hospital CTO-MA (2012): "Reorganization of the Hospital "Città della Scienza e della Salute" in Turin"
6. Fondazione Varesotto (2011): "Assessment and evaluation of health technologies within Hospital Authorities of Varese Province - AN.TE.VA"
7. Fadoi (2011): "Observational multi-centric no profit, study concerning the evaluation of diagnostic and therapeutic pathway of VTE"

Data Manager and Data Analyst	<p>Éupolis Lombardia – Istituto per la Ricerca, la Statistica e la Formazione Via Taramelli, 12 - 20124 Milano</p> <p>Analysis of cost data at "Accreditation, appropriateness, controls and territorial pharmaceuticals Structure" of Lombardy Region related to the following fields:</p> <ul style="list-style-type: none"> - Antiretroviral drugs (HIV, HBV and HCV) - Rheumatoid Arthritis - Retinopathy - Prosthetic assistance
Academic Experience	
Teaching Assistant	<p>Teaching Assistant at LIUC University (2009 – present):</p> <ul style="list-style-type: none"> - Adjunct Professor for teaching at the Master in the Coordination Functions for the Healthcare Professions (Topic: Benchmarking, Health Technology Assessment and Hospital-based Health Technology Assessment) - Adjunct Professor at Advanced Training Courses in Health Technology Assessment, in Management for Infectious Disease and in Ophthalmology (Topic: Health Technology Assessment) - Supervisor of thesis for the first level Master's Degree in the Coordination Functions for the Health Professions and Advanced Training Course in Health Technology Assessment
Publications	
	<p><u>International publications:</u></p> <p>Restelli U., Alberti A., Lazzarin A., Bonfanti M., Nappi C., Croce D. "Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy", <i>European Journal of Health Economics</i>, 19(1): 37-44, 2018.</p> <p>Restelli U., Rizzardini G., Antinori A., Lazzarin A., Bonfanti M., Bonfanti P., Croce D., "Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HI V-positive patients", <i>Therapeutics and Clinical Risk Management</i>, 13: 787–797, 2017.</p> <p>Foglia E., Lettieri E., Ferrario L., Porazzi E., Garagiola E., Pagani R., Bonfanti M., Lazzarotti V., Manzini R., Masella C., Croce D., Technology assessment in hospitals: lessons learned from an empirical experiment, <i>International Journal of Technology Assessment in Health Care</i>, 1-9, 2017.</p> <p>Restelli U., Alberti A., Lazzarin A., Bonfanti M., Nappi C., Croce D., "Cost effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) Vs. sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with Hepatitis C Virus genotype 3 in Italy", <i>The European Journal of Health Economics</i>, 1–8, 2016.</p> <p>Bonfanti M., Gambino ML., Pisani S., Carnevali I., Pinotti G., Croce D., Capella C., Sessa F., Tibiletti MG., "A cost analysis of inherited colorectal cancer care in Varese Province", <i>Journal of Cancer Policy</i>, 8: 1–6, 2016.</p> <p>Croce D., Bonfanti M., Restelli U., "Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectives", <i>Clinicoecon Outcomes Res.</i>, 8: 377-85, 2016.</p> <p>Restelli U., Alberti A., Lazzarin A., Bonfanti M., Nappi C., Croce D., "Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients", <i>Farmaceutica, Value Health</i>, 18 (7): A335–A766, 2015.</p>

	<p>Restelli U., Andreoni M., Antinori A., Bonfanti M., Di Perri G., Galli M., Lazzarin A., Rizzardini G., Croce D., “Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service”, <i>Clinico Economics and Outcomes Research</i>, 6: 409-414, 2014.</p> <p>Restelli U., Croce D., Porazzi E., Scolari F., Bonfanti M., Galli M., et al., “Health technology assessment in the HIV setting: the case of monotherapy”, <i>New Microbiologica</i>, 37: 247-261, 2014.</p> <p>Mauri G., Porazzi E., Cova L., Restelli U., Tondolo T., Bonfanti M., Cerri A., Ierace T., Croce D., Solbiati L., “Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment”, <i>Insights Imaging</i>, 5(1), 2014.</p> <p>Gussoni G., Foglia E., Frasson S., Casartelli L., Campanini M., Bonfanti M., Colombo F., Porazzi E., Ageno W., Vescovo G., Mazzone A., “Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients”, <i>Thrombosis & Haemostasis</i>, 131(1):17-23, 2013.</p> <p>Foglia E., Restelli U., Napoletano A.M., Coclite D., Porazzi E., Bonfanti M., Croce D., “Pressure ulcers management: economic evaluation and HTA”, <i>Journal of Preventive Medicine and Hygiene</i>, 53(1):30-6, 2012.</p>
Conferences	
	<p>ISPOR XX Annual European Congress, 6-8 Novembre 2017, Glasgow, Gran Bretagna. Restelli U., Bonfanti M., Rizzardini G., Moreno Guillen S., Grau Cerrato S., Metallidis S., Pacelli V., Soro M., Croce D. “Health service implications of the implementation of an early discharge strategy for patients admitted in infectious diseases departments in Southern Europe”, poster presentation.</p> <p>ISPOR XVIII Annual European Congress, 9-11 Novembre 2015, Milano. Restelli U., Bonfanti M., Alberti A., Lazzarin A., Nappi C., Croce D. “Cost Effectiveness Analysis of The Use of Daclatasvir for the Treatment of Hepatitis C Virus (HCV) Genotypes 3 in Cirrhotic Patients Within the Italian National Health Service”, poster presentation .</p> <p>ISPOR XVIII Annual European Congress, 9-11 Novembre 2015, Milano. Restelli U., Bonfanti M., Alberti A., Lazzarin A., Nappi C., Croce D. “Budget Impact Analysis of The Use of Daclatasvir for The Treatment of Hepatitis C Virus (HCV) Genotypes 3, In The Italian Setting”, poster presentation.</p> <p>Regione Lombardia, March 28th, 2014, Bonfanti M. e Foglia E., “Modelli di HB-HTA e loro applicabilità: analisi delle evidenze”, oral presentation</p> <p>SIMM, VI Congresso Nazionale, III Forum Internazionale, “SOS Servizio Sanitario Nazionale: Ultima chiamata”, November 21st-22nd, 2013, Bonfanti M., Porazzi E., Collo G., Falco S., Massazza G., “Nuovi modelli di organizzazioni ospedaliere: l’esperienza vincente del Week Hospital del P.O. CTO – Maria Adelaide di Torino”, oral presentation.</p> <p>HTAinternational, Annual Meeting 2013 “Evidence, Value, and Decision Making: Science or Art?”, June 15th-16th, 2013, Bonfanti M., Croce D., Foglia E., Porazzi E., Scolari F., “To assess or not to assess? CREMS Hospital-based HTA Solution for technologies”, poster presentation.</p> <p>Radiology Forum, “Progetti di Riorganizzazione e di Innovazione Tecnologica per il miglioramento della Qualità Assistenziale e il Contenimento dei Costi in Radiologia”, June 20th, 2013, Bonfanti M. e Porazzi E., “Come monitorare il livello di innovazione tecnologica del parco macchine per migliorare le performance e razionalizzare i costi”, oral presentation.</p>

	<p>ACOI, Convegno, May 9th 2013, Bonfanti M., “Il modello Hospital-based HTA sviluppato dal CREMS”, oral presentation.</p> <p>EHMA (European Health Management Association), Annual Conference 2012: “ Public Health Care: who pays, who provides?”, June 13rd-15th, 2012, Restelli U., Porazzi E., Morelli P., Foglia E., Bonfanti M., Ruspini M., Banfi G., "The use of Root Cause Analysis for error detection in Histology - impact on quality and safety of patients", poster presentation.</p> <p>IPSOR, 14Th Annual European Congress, November 5th-8th, 2011, Foglia E., Restelli U., Bonfanti M., Porazzi E., Bonizzoni E., Bonfanti P., Rizzardini G., Ricci E., Casartelli L., Croce D., “Lost in translation: a Markov model cost utility analysis of lopnavir/ritonavir vs atazanavir + ritonavir”, poster presentation.</p> <p>EHMA (European Health Management Association), Annual Conference 2011: “Integration in Health and Healthcare”, June 22nd-24th, 2011, Stefani I., Porazzi E., Foglia E., Bonfanti M., Poesio C., Calloni M. V., Perrone P., Mazzone A., Dotti C., “Call centre clinic: an innovative model for the integration of treatment in the hospital/territory”, poster presentation.</p>
Skills	
Technical Skills	Editing: Microsoft Word, Microsoft Excel, Microsoft Power Point, Microsoft Access Statistics: SAS and Eviews (basic)
Personal Skills	Aptitude for team working, sense of organization, effective communication skills

In compliance with the Italian Legislative Decree no. 196 dated June 30th, 2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance to art. 7 of the above mentioned decree.

Olgiate Olona, February 20th, 2019